/
Oncology
Advanced Non-Small Cell Lung Cancer
18
Pipeline Programs↗
13
Active Trials↗
10
Companies Involved↗
Advanced Non-Small Cell Lung Cancer is an emerging landscape with 18 programs across 10 companies. The most active players are Bayer, Pfizer. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 12
Phase 27
Approved
No programs
Analysis
Modality Breakdown
62%
Small molecule
8 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 78% of 18 pipeline programs.
Analysis
Trial Status
14
clinical trials
Recruiting7 · 50%
Active, not recruiting5 · 36%
Not yet recruiting1 · 7%
Available1 · 7%
Clinical Trials
Trial Activity
14 trials
A Phase II, Single-arm, Two-cohorts, Open-label, Single Center Study of Surufatinib or Surufatinib Combined With Vinorelbine as Third-line and Posterior Line Treatment in Patients With Non-Small Cell Lung Cancer
Active, not recruiting·AAffiliated Cancer Hospital & Institute of Guangzhou Medical University·Phase 2·NCT04922658·76 enrolled
A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07781202·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)